following a full submission:
durvalumab (Imfinzi®) is not recommended for use within NHSScotland.
Indication under review: In combination with platinum-based chemotherapy as neoadjuvant treatment, followed by durvalumab as monotherapy after surgery, is indicated for the treatment of adults with resectable (tumours ≥ 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known EGFR mutations or ALK rearrangements.
In a randomised, double-blind, phase III study, the addition of neoadjuvant and adjuvant durvalumab compared with the addition of placebo to neoadjuvant chemotherapy significantly improved complete pathological response and event-free survival in patients with resectable NSCLC.
The submitting company did not present a sufficiently robust economic analysis to gain acceptance by SMC.
Medicine details
- Medicine name:
- durvalumab (Imfinzi)
- SMC ID:
- SMC2677
- Indication:
In combination with platinum-based chemotherapy as neoadjuvant treatment, followed by durvalumab as monotherapy after surgery, is indicated for the treatment of adults with resectable (tumours ≥ 4 cm and/or node-positive) NSCLC and no known EGFR mutations or ALK rearrangements.
- Pharmaceutical company
- AstraZeneca UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 09 December 2024